RxDoctor Payments Data

Judith Knipple, MD

Internal Medicine · Rolling Meadows, ILNPI 1265426381

Payments from drug & device makers

$1,739in general payments, 2019–2025

Across 27 payments — averaging $64.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$844
  • Boehringer Ingelheim$353
  • Lilly USA, LLC$122
  • Axsome Therapeutics, Inc.$120
  • Amgen$120
  • Astellas Pharma US Inc$95
  • plus $85 from 1 others

What the payments were for

  • Food & beverage$1,63994%
  • Education$1006%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,739 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$233,139
Medicare patients
537
Services billed
2,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide39$47,926
EliquisApixaban40$43,913
JanuviaSitagliptin Phosphate27$24,844
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,344
MyrbetriqMirabegron22$17,821
FarxigaDapagliflozin Propanediol20$15,393
XareltoRivaroxaban16$13,234
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$4,788
Advair HfaFluticasone Propion/Salmeterol11$3,301
Levothyroxine Sodium270$3,001
SynthroidLevothyroxine Sodium31$2,761
Metoprolol Succinate97$2,070
Wixela InhubFluticasone Propion/Salmeterol11$2,000
Albuterol Sulfate HfaAlbuterol Sulfate75$1,905
Atorvastatin Calcium197$1,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$122$47,92639 claims
Astellas Pharma US IncMyrbetriq$95$17,82122 claims
Johnson & JohnsonXarelto$844$13,23416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Rolling Meadows

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →